Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK cell therapy in COVID-19 pneumonia
IRCT20200417047113N1Phase 2Completed
- Sponsor
- Middle East Gene Therapy
- Start
- Apr 2020
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AlloNK in coronavirus disease 2019 (COVID-19) and viral pneumonia (7 arms), sponsored by Middle East Gene Therapy. Primary endpoints: Fever, Cough and 7 more. Started Apr 2020; status: completed.
02
Drugs
AlloNK
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on IRCT20200417047113N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200417047113N1.